The Onco'Zine Brief with Peter Hofland

In this episode of The OncoZine Brief, Peter Hofland, Ph. D and Sonia Portillo talk with Gisela Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer at Excelixis. Following early work in model genetic systems, Exelixis, a genomics-based drug discovery company located in South San Francisco, CA, established a broad drug discovery and development platform that has...

In this edition of The OncoZine Brief, Peter Hofland, Ph. D and Sonia Portillo talk Sean McCarthy, D.Phil, President and Chief Executive Officer of CytomX, a biotechnology company developing a novel 'Probody Platform' which allows them to design therapeutic drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. In addition t...

In this episode of The OncoZine Brief, Peter Hofland, Ph. D and Sonia Portillo talk with Thomas Yankeelov, Ph. D, a computational biomedical engineer who came to The University of Texas at Austin from Vanderbilt University, where he served as the Ingram Professor of Cancer Research; professor of radiology and radiological sciences, physics, biomedical engineering and cancer biology; and director o...

In this edition of The OncoZine Brief, Peter Hofland, Ph. D and Sonia Portillo review some of the interesting studies presented at the 59th annual meeting of the American Society of Hematology – which took place December 9 – 12, 2017 in Atlanta, Georgia. They recap one of the most important healthcare conferences of the year, the annual meeting American Society of Hematology or ASH, one of these ‘...

In this episode of The Onco’Zine Brief Peter Hofland, Ph. D and Sonia Portillo are speaking with Joshua A. Hill, MD, an Associate in Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center in Seattle Washington. Dr. Hill is also an attending physician at the Seattle Cancer Care Alliance, as well as an Assistant Professor at the University of Washington. In today's show Hofland and...

In this Edition of The OncoZine Brief, brought to you from the 59th annual meeting of the American Society of Hematology held December 9-12, 2017 in Atlanta, Georgia, Peter Hofland, Ph. D and Sonia Portillo, B.Sc, the team behind the show, sat down with Phill Rowlands, Vice President and Head Oncology Therapeutic Area unit as well as Drug Development Management and Portfolio Management at Takeda P...

For this edition of The Onco'Zine Brief, recorded during 59th annual meeting of the American Society of Hematology held December 9 to 12, 2017 in Atlanta, Georgia, Peter Hofland and Sonia Portillo, the team behind show, sat down with Steven E. Benner, M.D., Senior Vice President and Therapeutic Area Head for Oncology at Astellas Pharma. In this interview Hofland and Portillo asks Benner about the...

In this edition of The Onco'Zine Brief, recorded during the 59th annual meeting of the American Society of Hematology - held December 9 to 12, 2017 in Atlanta, Georgia (USA), we talk with Anna Sureda, MD, Ph. D, Head of the Hematology Department at the Catalan Institute of Oncology, Barcelona, Spain - to discuss some of the exciting developments in the treatment of patients with Hodgkin’s lymphoma...

Even modest use of alcohol may increase cancer risk. The greatest risks are observed with heavy, long-term use of alcohol. Now, for the first time, the American Society of Clinical Oncology (ASCO) has formally recognized that alcohol drinking is a risk factor for multiple malignancies. This risk is, however, potentially modifiable.

Recorded during CPhI World Wide, October 24 - 27, 2017 in Frankfurt Germany, Peter Hofland and Sonia Portillo interview Charlie Johnson, the CEO of ADC Bio. ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.

In this episode of The Onco’Zine Brief hosts Peter Hofland, Ph. D and Sonia Portillo talk with Angela M. DeMichele, MD MSCE, Professor of Medicine and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs. The development of these promising new therapeutic agents is gener...

In this episode of The Onco'Zine Brief, Sonia Portillo and Peter Hofland ask Robert Z. Orlowski, MD, PhD, chairman, Ad Interim, Director of Myeloma and professor of Medicine in the Departments of Lymphoma, Myeloma and Experimental Therapeutics in the Division of Cancer Medicine at MD Anderson in Houston, Texas, about his thoughts and unique perspective on research and the recent advancements in th...

Lung cancer remains one of the most frequently diagnosed cancers. It is also one of the deadliest cancers – with each year more than 1.6 million tumor-related deaths worldwide. The correlation between smoking and mortality from lung cancer has been clearly confirmed and a decrease of mortality after cessation of tobacco use has been seen in the United States… Since the 1990s first in men and later...

In an Interview with Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, David R. Epstein BSc, MBA, the Executive Chairman of Rubius Therapeutics, explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases. Epstein explains how these novel drugs have leading applications in...

Each year, 1.4 million people are diagnosed with lung cancer worldwide. The 5-year survival rate for these patients is only 15.9%. In this episode, Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, interview Bonnie Adario, Cancer Survivor. Addario was was first diagnosed with stage 3b lung cancer in 2004, a cancer with a survival rate of only 5%. As part of her treatment, Adda...

Alice Crisci is a cancer survivor. As part of her journey Crisci founded Fertile Action, a cancer charity established to ensure fertile people touched by cancer can become mothers. As a cancer survivor and a single mom who faced issues of infertility, Alice dealt with the challenges of figuring out how preserve her fertility so that one day she could have a child. Her need resulted in the founding...

Recorded during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 2 - 6, 2017 in Chicago, Ill, Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, interview Dr. Steve Benner – Senior Vice President and Therapeutics Area Head of Oncology at Astellas Pharmaceuticals, and Mark Reisenauer, Senior Vice President, Oncology business unit at Astellas...

For this edition of The OncoZine Brief, we sat down with Jonathan E. Lim, M.D. co-founder of IGNYTA, and its President and Chief Executive Officer since July 2012. Lim is the Founder and Managing Partner at City Hill Ventures, a company he founded in 2010. He is also a Co-Founder of Bonti, Eclipse Therapeutics and served as the Chief Executive Officer and President of Halozyme Therapeutics from 20...

Patients living with invasive breast cancer with high levels of HER3 may face a significantly worse prognosis and decreased survival. This represents a large unmet medical need. Overexpression of epidermal growth factor receptors, also known as EGFR, such as HER2 and HER3, can play a role in cancer cell development, including breast cancer. Statistics show that one in five breast cancers overexpre...

Recorded during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the team behind The Onco'Zine Brief interviews Dr. Robert Andtbacka, associate professor in the Division of Surgical Oncology, at the Department of Surgery at the University of Utah School of Medicine, and surgeon and investigator with the Intermountain Healthcare and Huntsman Cancer Institute. He is a mem...

This episode of The Onco'Zine Brief is an interview with Nancy Brinker, founder of Susan G. Komen for the Cure. This program was originally recorded and broadcast during the Annual Meeting of the American Association of Cancer Research - AACR, held – April 16 – 20, 2016, in New Orleans, Louisiana. It can be said that Nancy Brinker embodies the global movement to end breast cancer. Over the last 4...

Even modest use of alcohol may increase cancer risk. The greatest risks are observed with heavy, long-term use of alcohol. Now, for the first time, the American Society of Clinical Oncology (ASCO) has formally recognized that alcohol drinking is a risk factor for multiple malignancies. This risk is, however, potentially modifiable.

In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo talk with Robert Z. Orlowski, MD, PhD, chairman, Ad Interim, Director of Myeloma and Professor of Medicine in the Departments of Lymphoma, Myeloma and Experimental Therapeutics in the Division of Cancer Medicine at MD Anderson in Houston, Texas. They ask Orlowski about his thoughts and unique perspective on research and the r...

Born and raised in Curaçao NA, an island in the southern Caribbean Sea, Bob Pinedo, MD, PhD, now professor emeritus and a consultant to the Board of the Free University Medical Center in Amsterdam, The Netherlands, remains a real powerhouse in the World of Oncology. He has spent more than 40 years researching cancer biology, drug treatment and resistance, and it can be said that his accomplishment...

This episode of The Onco'Zine Brief is an interview with Michael A. Caligiuri, MD, the current president of the American Association for Cancer Research | AACR, recorded during the 2017 annual meeting of organization. For more information visit The Onco'Zine Brief: http://www.oncozine.com